Indigo

Indigo, founded in 2016 and headquartered in Belgium, is a promising player in the Health Care and Medical Devices industries. The company is committed to "lighting up the lives of millions of people living with chronic disease", demonstrating a strong social mission.

Indigo is pioneering in the development of an innovative medical device—a subcutaneously implanted Continuous Multi-Metabolite Monitoring (CMM®) sensor. This device leverages proprietary nanophotonics technology to offer real-time monitoring of metabolites, such as glucose, ketone, and lactate, without the need for external devices. Initially targeting diabetes, this technology presents a disruptive solution in chronic disease management.

In its latest financing round, Indigo secured a €38.00M Series B investment on 27 July 2020, backed by notable investors including Ackermans & van Haaren, Imec.xpand, PMV, and others, indicating strong confidence in the company's potential.